Mostrar el registro sencillo

A multi-center, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma

dc.contributor.authorQuach, Hang
dc.contributor.authorParmar, Gurdeep
dc.contributor.authorOcio San Miguel, Enrique María 
dc.contributor.authorPrince, H. Miles
dc.contributor.authorOriol, Albert
dc.contributor.authorCrowther, Helen
dc.contributor.authorTsukada, Nobuhiro
dc.contributor.authorBories, Pierre
dc.contributor.authorMadan, Sumit
dc.contributor.authorNathwani, Nitya
dc.contributor.authorSunami, Kazutaka
dc.contributor.authorSemiond, Dorothee
dc.contributor.authorYu, Disa
dc.contributor.authorCordero, Paul
dc.contributor.authorMacé, Sandrine
dc.contributor.authorSuzan, Florence
dc.contributor.authorMoreau, Philippe
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2024-11-27T15:08:19Z
dc.date.available2024-11-27T15:08:19Z
dc.date.issued2024
dc.identifier.issn0390-6078
dc.identifier.issn1592-8721
dc.identifier.urihttps://hdl.handle.net/10902/34533
dc.description.sponsorshipFunding: this study was funded by Sanofi. Acknowledgments: the authors thank the participating patients and their caregivers, the study centers, and the study investigators for their contributions to the study. The authors also thank Honghong Dong, MS, of Sanofi Research & Development, Bridgewater NJ, USA, for her contribution to the statistical analyses for this study, and BioCytex (a Stago Group company) for their contribution to the immunophenotyping analyses. The on-body delivery system was manufactured by Enable Injections, Inc. Medical writing support was provided by S. Mariani, MD, PhD of Envision Pharma Group, funded by Sanofi.es_ES
dc.format.extent23 p.es_ES
dc.language.isoenges_ES
dc.publisherFerrata Storti Foundationes_ES
dc.rights© Ferrata Storti Foundation. Hang Quach es al., 2024, A multi-center, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple mieloma. Obtained from the Haematologica Journal website http://www.haematologica.org. Creative Commons Reconocimiento-NoComercial.es_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.sourceHaematologica, 2024es_ES
dc.titleA multi-center, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myelomaes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://doi.org/10.3324/haematol.2023.284730es_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.3324/haematol.2023.284730
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail
Nombre:
MultiCenterPhase.pdf
Tamaño:
485.4Kb
Formato:
PDF
Descripción:
MultiCenterPhase

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

© Ferrata Storti Foundation. Hang Quach es al., 2024, A multi-center, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple mieloma. Obtained from the Haematologica Journal website http://www.haematologica.org. Creative Commons Reconocimiento-NoComercial.Excepto si se señala otra cosa, la licencia del ítem se describe como © Ferrata Storti Foundation. Hang Quach es al., 2024, A multi-center, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple mieloma. Obtained from the Haematologica Journal website http://www.haematologica.org. Creative Commons Reconocimiento-NoComercial.